--AccuStem Sciences, Inc., a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, and EmeritusDX, a rapidly growing cancer diagnostics and ...
AccuStem Sciences is set to launch the microRNA Signature Classifier (MSC) blood test for the US lung cancer screening programmes. The company aims to broaden the test's use to the 15 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results